Clinical Trial Update: Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) [Phase 2]

View source ↗

Summary

Phase 2 trial exploring pembrolizumab with paclitaxel and cisplatin followed by surgery for locally advanced esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Squamous Cell Carcinoma, Stage III | Phase 2 | Status: UNKNOWN